SOPHIA ANTIPOLIS, France--(BUSINESS WIRE)--Regulatory News:
MEDIAN Technologies (Paris:ALMDT), a leading medical imaging solutions and service provider for image interpretation and management in oncology, announced a doubling of its order backlog (*) in one year.
At 31 December 2015, the company’s order backlog stood at €21.3M,
compared to €11M at 31 December 2014. This figure includes contract
cancellations amounting to €2.46M in the last quarter of the financial
For comparison, on 30 June 2015 the order backlog stood at €18.26M.
In terms of order intake, since October 2015 MEDIAN has recorded €2.86M worth of new orders, consisting of a signed contract for €1.14M with one of the top 20 pharmaceutical companies, and €1.72M in new project awards**.
MEDIAN also posted turnover for financial year 2015 of €3.9M versus €1.5M at 31 December 2014. This major increase in turnover testifies to the numerous advances that MEDIAN has made in its field of business, particularly in clinical trials.
(*) Order backlog refers to customers’ orders that have been received but not invoiced yet.
(**) A project award is a notification announcing that the company's solution has been selected for a specific project. This should result in a signed contract within 18 months, subject to upstream clinical results.
About MEDIAN Technologies: MEDIAN Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. MEDIAN Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. MEDIAN serves two primary markets: drug development and patient care. MEDIAN has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, MEDIAN Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. MEDIAN has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia. MEDIAN has received the label "Innovative company" by the BPI and is listed on Euronext Paris' Alternext market. ISIN: FR0011049824– ticker: ALMDT The company is eligible for the PEA PME SME equity savings plan setup. For more information on MEDIAN, please visit: www.mediantechnologies.com
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”